-
公开(公告)号：US20080085860A1
公开(公告)日：2008-04-10
申请号：US11573896
申请日：2005-08-11
申请人： Bengt Krister Bokvist , John Phillip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
发明人： Bengt Krister Bokvist , John Phillip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
CPC分类号： C07K14/57563 , A61K38/00
摘要： The present invention encompasses PEGylated peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
摘要翻译： 本发明包括选择性活化VPAC2受体并可用于治疗糖尿病的聚乙二醇化肽。
-
公开(公告)号：US20080146500A1
公开(公告)日：2008-06-19
申请号：US11573830
申请日：2005-08-11
申请人： Bengt Krister Bokvist , John Philip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
发明人： Bengt Krister Bokvist , John Philip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
CPC分类号： A61K47/60
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
摘要翻译： 本发明包括选择性活化VPAC2受体并可用于治疗糖尿病的肽。
-
公开(公告)号：US20090118167A1
公开(公告)日：2009-05-07
申请号：US11573917
申请日：2005-08-11
申请人： Bengt Krister Bokvist , John Philip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
发明人： Bengt Krister Bokvist , John Philip Mayer , Lianshan Zhang , Jorge Alsina-Fernandez , Andrew Mark Vick
IPC分类号： A61K38/17 , C07K14/475
CPC分类号： A61K47/60
摘要： The invention provides VPAC2R peptide agonists coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide.
摘要翻译： 本发明提供了与至少一种聚乙二醇分子或其衍生物偶联的VPAC2R肽激动剂，当与未PEG化肽相比时，产生具有延长的半衰期和较慢清除率的生物活性肽。
-
公开(公告)号：US20080113905A1
公开(公告)日：2008-05-15
申请号：US10548328
申请日：2004-03-19
申请人： Richard Dennis DiMarchi , Wolgang Glaesner , John Lee Millican Jr , Andrew Mark Vick , Lianshan Zhang
发明人： Richard Dennis DiMarchi , Wolgang Glaesner , John Lee Millican Jr , Andrew Mark Vick , Lianshan Zhang
IPC分类号： A61K38/26 , C07K14/605 , A61P3/10 , A61P9/10 , A61P1/14
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与至少一种聚乙二醇分子或其衍生物偶联的GLP-1化合物，当与未PEG化肽相比时，产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗糖尿病，肥胖症，肠易激综合征和其他通过降低血浆葡萄糖，抑制胃和/或肠蠕动并抑制胃和/或肠排空或抑制食物而受益的病症 摄入量
-
公开(公告)号：US20090215981A1
公开(公告)日：2009-08-27
申请号：US11913365
申请日：2006-05-11
申请人： Wolfgang Glaesner , John Philip Mayer , Rohn Lee Millican, JR. , Andrew Mark Vick , Lianshan Zhang
发明人： Wolfgang Glaesner , John Philip Mayer , Rohn Lee Millican, JR. , Andrew Mark Vick , Lianshan Zhang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04 , A61P3/10
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility.
摘要翻译： 本发明提供了与两个聚乙二醇分子或其衍生物偶联的GLP-1化合物，当与未PEG化肽相比时，产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗通过降低血糖，减少食物摄入，减少胃或肠排空，增加β（β）细胞群体或减少胃或肠蠕动而受益的病症或障碍。
-
公开(公告)号：US07557183B2
公开(公告)日：2009-07-07
申请号：US10548328
申请日：2004-03-19
申请人： Richard Dennis DiMarchi , Wolfgang Glaesner , Rohn Lee Millican, Jr. , Andrew Mark Vick , Lianshan Zhang
发明人： Richard Dennis DiMarchi , Wolfgang Glaesner , Rohn Lee Millican, Jr. , Andrew Mark Vick , Lianshan Zhang
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与至少一种聚乙二醇分子或其衍生物偶联的GLP-1化合物，当与未PEG化肽相比时，产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗糖尿病，肥胖症，肠易激综合征和其它通过降低血浆葡萄糖，抑制胃和/或肠蠕动并抑制胃和/或肠排空或抑制食物而受益的条件 摄入量
-
公开(公告)号：US08183340B2
公开(公告)日：2012-05-22
申请号：US11913365
申请日：2006-05-11
申请人： Wolfgang Glaesner , John Philip Mayer , Rohn Lee Millican, Jr. , Andrew Mark Vick , Lianshan Zhang
发明人： Wolfgang Glaesner , John Philip Mayer , Rohn Lee Millican, Jr. , Andrew Mark Vick , Lianshan Zhang
IPC分类号： A61K38/26 , C07K14/605 , A61P3/10
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (β) cell population, or decreasing gastric or intestinal motility.
摘要翻译： 本发明提供了与两个聚乙二醇分子或其衍生物偶联的GLP-1化合物，当与未PEG化肽相比时，产生具有延长的半衰期和较慢清除率的生物活性肽。 这些聚乙二醇化GLP-1化合物和组合物可用于治疗通过降低血糖，减少食物摄取，减少胃或肠排空，增加β（β）细胞群体或减少胃或肠运动而受益的病症或病症。
-
公开(公告)号：US07452966B2
公开(公告)日：2008-11-18
申请号：US10558627
申请日：2004-06-10
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与特异性IgG4-Fc衍生物融合的特异性GLP-1类似物。 这些融合蛋白具有增加的半衰期，免疫原性降低，并降低效应子活性。 融合蛋白可用于治疗糖尿病，肥胖症，肠易激综合征和其它通过降低血浆葡萄糖，抑制胃和/或肠运动并抑制胃和/或肠排空或抑制食物摄取而受益的病症。
-
公开(公告)号：US08273854B2
公开(公告)日：2012-09-25
申请号：US12262832
申请日：2008-10-31
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与特异性IgG4-Fc衍生物融合的特异性GLP-1类似物。 这些融合蛋白具有增加的半衰期，免疫原性降低，并降低效应子活性。 融合蛋白可用于治疗糖尿病，肥胖症，肠易激综合征和其它通过降低血浆葡萄糖，抑制胃和/或肠运动并抑制胃和/或肠排空或抑制食物摄取而受益的病症。
-
公开(公告)号：US20090074769A1
公开(公告)日：2009-03-19
申请号：US12262832
申请日：2008-10-31
IPC分类号： A61K39/395 , A61P3/10
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与特异性IgG4-Fc衍生物融合的特异性GLP-1类似物。 这些融合蛋白具有增加的半衰期，免疫原性降低，并降低效应子活性。 融合蛋白可用于治疗糖尿病，肥胖症，肠易激综合征和其它通过降低血浆葡萄糖，抑制胃和/或肠运动并抑制胃和/或肠排空或抑制食物摄取而受益的病症。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.031 秒)